Webcasts

What does 2010 have in store for dealmakers?

Is there light at the end of the tunnel? Whilst the financial crisis caused a significant drop in deal activity in the first half of the year, the second half saw a marked improvement. In particular, private equity firms, initially shell shocked by the near collapse of the global financial crisis and the freezing of the credit markets, rallied and were engaged in deals by the end of 2009. Key questions for 2010 are: will recovery continue and how strong will recovery be?

PLAY PODCAST

Episode 2: “Investor Transparency: The MFA guidelines and Selective Disclosure”

Kelli Moll, partner, Schulte, Roth & Zabel LLP, discusses the MFA guidelines for establishing greater transparency between investors and fund managers and how to address the issue of selective disclosure.

Episode 1: “What you need to know about U.S. and EU Proposed Legislation: New Regulation Requirements and Assessing Systemic Risk”

Listen to Kelli Moll, partner, Schulte Roth & Zabel LLP discuss the proposed hedge fund regulations and their approach to systemic risk.

Pharma companies are seeking to bolster pipelines and cut costs more than ever before in preparation for looming patent expirations of blockbuster drugs. In this environment global collaborations are increasing while budgets are shrinking, and as a result Internet-based communication has taken a prominent position in clinical development.

PLAY WEBCAST

The return on investment from using a clinical trial portal to manage document exchange and communication with investigative sites versus using traditional paper-based methods is clear. From reducing study start-up cycle time to expediting document distribution and management during conduct and close-out, the time and money savings are measurable. In addition, there are added benefits of security and control that come with using a portal that contribute to ROI.

PLAY WEBCAST